Sobi Receives European Commission Approval for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN Aspaveli (pegcetacoplan) is the first treatment of primary IC-MPGN and the first treatment for C3G and primary IC-MPGN for patients 12 years and older STOCKHOLM, Jan. 16, 2026 /PRNewswire/ -- Sobi® (STO: SOBI),...